Article information
Full text is only aviable in PDF
References
[1.]
C. ooper, D. Doherty, G. Haugen, B. Kloos, R. Lee, S. Mandel, Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer, et al.
The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
Thyroid, 19 (2009), pp. 1167-1214
[2.]
R. Görges, G. Kahaly, J. Muller-Brand, H. Mäcke, H.W. Roser, A. Bockisch.
Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
Thyroid, 11 (2001), pp. 647-659
[3.]
J.J. Teunissen, D.J. Kwekkeboom, E.P. Krenning.
Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
Trend Endocrinol Metab, 17 (2006), pp. 19-25
[4.]
N.J. Sarlis, L. Gourgiotis, L.C. Guthrie, B. Galen, M.C. Skarulis, T.H. Shawker, et al.
In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer comparison with F-18 FDG positron emission tomography and extensive conventional radiographic image.
Clin Nucl Med, 28 (2003), pp. 208-217
[5.]
R.J. Robbins, R.H. Hill, G.W. Wang, H.H. Macapinlac, S.M. Larson.
Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue.
Thyroid, 10 (2000), pp. 177-183
[6.]
S. Krantic.
Peptides as regulators of the immune system: emphasis on somatostatin.
Peptides, 21 (2000), pp. 1941-1964
[7.]
D.J. Kwekkeboom, J. Mueller-Brand, G. Paganelli, L.B. Anthony, S. Pawels, L.K. Kvols, et al.
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
J Nucl Med, 46 (2005), pp. S62-S66
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
